Literature DB >> 1939961

Effects of pacing rate and timing of defibrillation shock on the relation between the defibrillation threshold and the upper limit of vulnerability in open chest dogs.

P S Chen1, G K Feld, M M Mower, B B Peters.   

Abstract

To test the relation between the defibrillation threshold and the upper limit of vulnerability, the shock strength associated with 50% probability of successful defibrillation (DFT50) and that associated with 50% probability of reaching the upper limit of vulnerability (ULV50) were determined in 20 open chest dogs with use of the delayed up-down method, with pacing drive cycle lengths of 150 to 500 ms and either single 6-ms shocks (10 dogs) or 12-ms biphasic shocks (10 dogs) given at the mid-upslope, peak and mid-downslope of the T wave of electrocardiographic lead II. The shocks were given by means of a patch-patch configuration on the anterior and posterior surfaces of the heart, which was paced from a stimulating electrode attached to the left ventricular apex. Analysis of variance showed no statistically significant differences in ULV50 as determined with different pacing cycle lengths. For monophasic shocks, DFT50 (331 +/- 66 V or 5.8 +/- 2.7 J) was not significantly different from ULV50 determined at the mid-upslope of the T wave (318 +/- 64 V or 5 +/- 2 J). The correlation coefficients between the two values were 0.74 (p = 0.014) for voltage and 0.67 (p = 0.034) for energy. In contrast, DFT50 was significantly higher than ULV50 as determined at the peak of the T wave (219 +/- 43 V or 2.3 +/- 1 J) and mid-downslope of the T wave (200 +/- 38 V or 1.9 +/- 0.9 J). In three dogs, ventricular fibrillation could not be induced at the mid-downslope of the T wave with any baseline pacing (Si) cycle length.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1939961     DOI: 10.1016/0735-1097(91)90690-b

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Differences between left and right ventricular chamber geometry affect cardiac vulnerability to electric shocks.

Authors:  Blanca Rodríguez; Li Li; James C Eason; Igor R Efimov; Natalia A Trayanova
Journal:  Circ Res       Date:  2005-06-23       Impact factor: 17.367

Review 2.  The role of transmural ventricular heterogeneities in cardiac vulnerability to electric shocks.

Authors:  Thushka Maharaj; Robert Blake; Natalia Trayanova; David Gavaghan; Blanca Rodriguez
Journal:  Prog Biophys Mol Biol       Date:  2007-08-22       Impact factor: 3.667

3.  The role of mechanoelectric feedback in vulnerability to electric shock.

Authors:  Weihui Li; Viatcheslav Gurev; Andrew D McCulloch; Natalia A Trayanova
Journal:  Prog Biophys Mol Biol       Date:  2008-02-16       Impact factor: 3.667

4.  Correlation of acute and chronic defibrillation threshold with upper limit of vulnerability determined in normal sinus rhythm.

Authors:  U Birgersdotter-Green; K Undesser; O Fujimura; G K Feld; R M Kass; W J Mandel; C T Peter; P S Chen
Journal:  J Interv Card Electrophysiol       Date:  1999-07       Impact factor: 1.900

5.  [Influence of waveform and configuration of electrodes on the defibrillation threshold of implantable cardioverter-defibrillators].

Authors:  M Block; D Hammel; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1997-03

6.  Three-dimensional mechanisms of increased vulnerability to electric shocks in myocardial infarction: altered virtual electrode polarizations and conduction delay in the peri-infarct zone.

Authors:  Lukas J Rantner; Hermenegild J Arevalo; Jason L Constantino; Igor R Efimov; Gernot Plank; Natalia A Trayanova
Journal:  J Physiol       Date:  2012-05-14       Impact factor: 5.182

7.  Arrhythmogenesis in the heart: Multiscale modeling of the effects of defibrillation shocks and the role of electrophysiological heterogeneity.

Authors:  Hermenegild Arevalo; Blanca Rodriguez; Natalia Trayanova
Journal:  Chaos       Date:  2007-03       Impact factor: 3.642

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.